Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080166 · ClinicalTrials.gov registry record · NA
UPLYFT For Lymphoma Survivors
A NA study of Lymphoma and Survivorship, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT05080166 is a NA study of Lymphoma and Survivorship that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 74 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05080166, a NA study of Lymphoma and Survivorship, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Conditions Studied
Interventions
- OTHER Interview with Clinicians
- OTHER Field Test of UPLYFT with Lymphoma Survivors
- BEHAVIORAL Pilot of UPLYFT with Lymphoma Survivors
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05080166
The ClinicalTrials.gov registry entry for NCT05080166 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Interview with Clinicians is the first listed.
NCT05080166 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05080166 about?
NCT05080166 is a clinical study titled "UPLYFT For Lymphoma Survivors". The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivor...
What is the current status of trial NCT05080166?
This trial is currently recruiting. It is a NA study. The enrollment target is 74 participants. The study started on 2022-02-08. Estimated completion is 2026-08-31.
What conditions does trial NCT05080166 study?
This clinical trial studies the following conditions: Lymphoma, Survivorship.
What interventions are being tested in trial NCT05080166?
The interventions under investigation include: Interview with Clinicians (OTHER), Field Test of UPLYFT with Lymphoma Survivors (OTHER), Pilot of UPLYFT with Lymphoma Survivors (BEHAVIORAL).
Who is sponsoring clinical trial NCT05080166?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05080166 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.